Pulmonx Corp (LUNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmonx Corp (LUNG) has a cash flow conversion efficiency ratio of -0.136x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.16 Million) by net assets ($60.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pulmonx Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Pulmonx Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pulmonx Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
Pulmonx Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmonx Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phinergy Ltd
TA:PNRG
|
-0.359x |
|
K Auction Inc.
KQ:102370
|
0.025x |
|
Incross Co. Ltd
KQ:216050
|
0.049x |
|
Forum Markets, Incorporated
NASDAQ:FRMM
|
-0.037x |
|
Nebag ag
SW:NBEN
|
0.001x |
|
Santova Ltd
JSE:SNV
|
0.078x |
|
Toung LoongTextile Mfg Co Ltd
TWO:4401
|
0.064x |
|
Sports Entertainment Group Ltd
AU:SEG
|
0.082x |
Annual Cash Flow Conversion Efficiency for Pulmonx Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Pulmonx Corp from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Pulmonx Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $85.81 Million | $-31.54 Million | -0.368x | -15.62% |
| 2023-12-31 | $118.31 Million | $-37.61 Million | -0.318x | -8.46% |
| 2022-12-31 | $154.01 Million | $-45.14 Million | -0.293x | -36.70% |
| 2021-12-31 | $193.24 Million | $-41.43 Million | -0.214x | -58.27% |
| 2020-12-31 | $226.13 Million | $-30.63 Million | -0.135x | -222.24% |
| 2019-12-31 | $-187.38 Million | $-20.77 Million | 0.111x | +0.81% |
| 2018-12-31 | $-167.33 Million | $-18.39 Million | 0.110x | -99.85% |
| 2017-12-31 | $-63.18K | $-4.64 Million | 73.407x | +10136.98% |
| 2016-12-31 | $-2.84 Million | $-2.03 Million | 0.717x | -25.61% |
| 2015-12-31 | $-2.65 Million | $-2.56 Million | 0.964x | +1.67% |
| 2014-12-31 | $-1.41 Million | $-1.34 Million | 0.948x | +107.46% |
| 2013-12-31 | $-1.78 Million | $-811.78K | 0.457x | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more